In vitro determination of uptake, retention, distribution, biological efficacy, and toxicity of boronated compounds for neutron capture therapy: a comparison of porphyrins with sulfhydryl boron hydrides.
A major problem remaining in the evaluation of boronated compounds for neutron capture therapy (NCT) is the need to know the intra- or extracellular microdistribution of boron. This is a consequence of the short range of the 10B(n,alpha)7Li reaction products (approximately 10 microns), such that biological efficacy is dependent upon intracellular distribution. In particular, if boron location is predominantly extracellular, a significant reduction in efficacy would be expected. The in vitro procedure described here was developed mainly to provide information regarding the intra- and extracellular location and concentration of boron. However, use of the technique also allows the measurement of compound uptake and retention (binding) and the determination of biological efficacy by the evaluation of survival curves obtained following irradiation with thermal neutrons. Comparison is made to results obtained with boric acid (H3(10)BO3) and to results calculated for various boron distributions. Concomitantly, an indication of compound toxicity can be obtained from the plating efficiency of unirradiated control cells. Currently, most investigators utilize in vivo systems for testing and evaluating boron uptake from various carrier molecules. Given the large number of boron compounds being synthesized and needing evaluation as to their usefulness for NCT, the in vitro technique described here is simple and advantageous for initial compound screening. In addition to sparing animal lives, it is both time and cost effective and utilizes much smaller quantities of test compound than are required for an in vivo assay. A boronated porphyrin (BOPP) evaluated by the above procedure shows an uptake and retention approximately 20 times that of sulfhydryl boron hydride monomer (BSH); the latter compound is currently being used clinically for NCT in Japan and is anticipated for use in clinical trials in the United States. If the advantages demonstrated by BOPP in these in vitro studies are validated in animal experiments, BOPP should be considered for clinical application.
Fairchild
R G
RG
Brookhaven National Laboratory, Upton, New York 11973.
Kahl
S B
SB
Laster
B H
BH
Kalef-Ezra
J
J
Popenoe
E A
EA
D000818:Animals; D001880:Boranes / Q000138:chemical synthesis / Q000494:pharmacology*; D001894:Borohydrides; D001895:Boron / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects* / Q000528:radiation effects; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects* / Q000528:radiation effects; D004307:Dose-Response Relationship, Radiation; D007554:Isotopes; D007700:Kinetics; D009502:Neutrons; D011878:Radiotherapy / Q000379:methods*; D013438:Sulfhydryl Compounds / Q000138:chemical synthesis / Q000494:pharmacology*; D013440:Sulfides / Q000138:chemical synthesis / Q000494:pharmacology*
D001880:Boranes; D001894:Borohydrides; D007554:Isotopes; D013438:Sulfhydryl Compounds; D013440:Sulfides; C014651:mercaptoundecahydrododecaborate; C060304:sulfhydryl borane dimer; D001895:Boron